title: Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.
abstract: We report the cloning and characterization of the gyrA gene of the Mycoplasma hominis DNA gyrase, which was previously shown to be associated with quinolone resistance in this organism. The 2,733-bp gyrA gene encodes a protein of 911 amino acids with a calculated molecular mass of 102.5 kDa. As expected, M. hominis GyrA exhibits higher homology with the GyrA subunits of the gram-positive bacteria Clostridium acetobutylicum, Bacillus subtilis, Streptococcus pneumoniae, and Staphylococcus aureus than with its Escherichia coli counterpart. Knowing the entire sequence of the gyrA gene of M. hominis could be very useful for confirming the role of the GyrA subunit in fluoroquinolone resistance. Twenty-nine mutants of M. hominis were selected stepwise for resistance to trovafloxacin, a new potent fluoroquinolone, and their gyrA, gyrB, parC, and parE quinolone resistance-determining regions were characterized. Three rounds of selection yielded 3 first-step, 12 second-step, and 14 third-step mutants. The first-step mutants harbored a single substitution, Glu460-->Lys (E. coli coordinates), in ParE. GyrA changes, Ser83-->Leu, Glu87-->Lys, and Ala119-->Glu or Val, were found only in the second round of selection. At the third step, additional substitutions, at ParC Ser80, Ser81, and Glu84 and ParE Leu440, associated with high-level resistance to fluoroquinolones, appeared. Thus, high-level resistance to trovafloxacin required three steps and was associated with alterations in both fluoroquinolone targets. According to these genetic data, in M. hominis, as in Staphylococcus aureus and Streptococcus pneumoniae, topoisomerase IV seems to be the primary target of trovafloxacin.
authors.affiliation: Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 33076 Bordeaux, France. cecile.bebear@u-bordeaux2.fr
authors.forename: C M
authors.initials: CM
authors.lastname: Bébéar
authors.forename: O
authors.initials: O
authors.lastname: Grau
authors.forename: A
authors.initials: A
authors.lastname: Charron
authors.forename: H
authors.initials: H
authors.lastname: Renaudin
authors.forename: D
authors.initials: D
authors.lastname: Gruson
authors.forename: C
authors.initials: C
authors.lastname: Bébéar
mesh_terms: D000595:Amino Acid Sequence; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics; D001483:Base Sequence; D003001:Cloning, Molecular; D027081:DNA Gyrase; D027101:DNA Topoisomerase IV; D004250:DNA Topoisomerases, Type II / Q000235:genetics*; D004269:DNA, Bacterial / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics; D004352:Drug Resistance, Microbial; D016521:Electrophoresis, Gel, Pulsed-Field; D024841:Fluoroquinolones; D008969:Molecular Sequence Data; D009154:Mutation / Q000235:genetics; D019535:Mycoplasma hominis / Q000235:genetics*; D009287:Naphthyridines / Q000494:pharmacology*; D010957:Plasmids / Q000276:immunology; D015183:Restriction Mapping; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000890:Anti-Infective Agents; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D004268:DNA-Binding Proteins; D024841:Fluoroquinolones; D009287:Naphthyridines; C080163:trovafloxacin; D027101:DNA Topoisomerase IV; D027081:DNA Gyrase; D004250:DNA Topoisomerases, Type II